Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Issue 5 (28th May 2019)

• Record Type: Journal Article
• Authors: Pham, Ba'; Thomas, Sonia M; Lillie, Erin; Lee, Taehoon; Hamid, Jemila; Richter, Trevor; Janoudi, Ghayath; Agarwal, Arnav; Sharpe, Jane P; Scott, Alistair; Warren, Rachel; Brahmbhatt, Ronak; Macdonald, Erin; Straus, Sharon E; Tricco, Andrea C
• Is Part Of: BMJ open. Volume 9:Issue 5(2019)
• Publication Date: 2019-05-28
• Subjects: ranibizumab -- bevacizumab -- aflibercept -- anti-vascular endothelial growth factor -- age-related macular degeneration -- diabetic macular edema -- retinal vein occlusion -- myopic choroidal neovascularization; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-022031
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To evaluate the comparative effectiveness and safety of intravitreal bevacizumab, ranibizumab and aflibercept for patients with choroidal neovascular age-related macular degeneration (cn-AMD), diabetic macular oedema (DMO), macular oedema due to retinal vein occlusion (RVO-MO) and myopic choroidal neovascularisation (m-CNV). Design: Systematic review and random-effects meta-analysis. Methods: Multiple databases were searched from inception to 17 August 2017. Eligible head-to-head randomised controlled trials (RCTs) comparing the (anti-VEGF) drugs in adult patients aged ≥18 years with the retinal conditions of interest. Two reviewers independently screened studies, extracted data and assessed risk of bias. Results: 19 RCTs involving 7459 patients with cn-AMD (n=12), DMO (n=3), RVO-MO (n=2) and m-CNV (n=2) were included. Vision gain was not significantly different in patients with cn-AMD, DMO, RVO-MO and m-CNV treated with bevacizumab versus ranibizumab. Similarly, vision gain was not significantly different between cn-AMD patients treated with aflibercept versus ranibizumab. Patients with DMO treated with aflibercept experienced significantly higher vision gain at 12 months than patients receiving ranibizumab or bevacizumab; however, this difference was not significant at 24 months. Rates of systemic serious harms were similar across anti-VEGF agents. Posthoc analyses revealed that an as-needed treatment regimen (6–9 injections per year) was associated with a mortality increase of 1.8% (risk ratio: 2.0 [1.2 to 3.5], 2 RCTs, 1795 patients) compared with monthly treatment in cn-AMD patients. Conclusions: Intravitreal bevacizumab was a reasonable alternative to ranibizumab and aflibercept in patients with cn-AMD, DMO, RVO-MO and m-CNV. The only exception was for patients with DME and low visual acuity (<69 early treatment diabetic retinopathy study [ETDRS] letters), where treatment with aflibercept was associated with significantly higher vision gain (≥15 ETDRS letters) than bevacizumab or ranibizumab at 12 months; but the significant effects were not maintained at 24 months. The choice of anti-VEGF drugs may depend on the specific retinal condition, baseline visual acuity and treatment regimen. PROSPERO registration number: CRD42015022041 .